<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01300286</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00024305</org_study_id>
    <nct_id>NCT01300286</nct_id>
  </id_info>
  <brief_title>Open Label Use Of RiaStap During Aortic Reconstruction</brief_title>
  <official_title>Open Label Use Of RiaStap During Aortic Reconstruction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>CSL Behring</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Duke University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The overall purpose of this study is to administer fibrinogen concentrate (RiaSTAP, CSL
      Behring, Marburg, Germany) with the goal of treating coagulopathic bleeding by improving
      hemostasis thereby reducing overall blood product transfusion after separation from
      cardiopulmonary bypass following aortic reconstructive surgery. With the current sample size
      this is a pilot study and in effect will determine the fibrinogen level response to
      fibrinogen concentrate administered during aortic reconstructive surgery. It will be
      underpowered to detect reduction in bleeding but comparison to historical controls will be
      included as a secondary outcome.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study design Open-label study Inclusion criteria Elective, adult aortic reconstruction
      involving a hemi-arch replacement at Duke University Medical Center (DUMC).

      Exclusion criteria Concomitant procedures such as Coronary Artery Bypass Grafting (CABG) ,
      stents (within the last 3 years), refusal of blood transfusion, recent Myocardial Infarction
      (MI) (within the last 3 months), pregnancy, INR &gt; 1.1, platelet inhibitor drugs within 5 days
      of surgery (aspirin 325 mg within 48 hours of surgery), platelet count &lt; 150,000, age &lt;18
      years, inability to obtain written informed consent, known coagulopathy including a history
      of recent coumadin therapy.

      Primary outcome variable Fibrinogen level Secondary outcome variables Total blood product
      units administered during post op day (POD) 0, 1, 2, 12 and 24 hour chest tube drainage,
      ventilator time, duration of oxygen dependency, renal dysfunction. Adverse events will be
      recorded.

      Study procedure The administration of RiaSTAP is detailed in the flowchart below.

      Projected milestones Based on recent surgical volume and assuming a conservative recruitment
      in the 60-70% range we will plan to complete the study of 22 patients as determined by
      budgetary constraints in a projected 12-month study period.

      We plan to evaluate the protocol after 11 (half of the) patients. Reevaluation and
      modification may include broadening the inclusion criteria and/or altering our transfusion
      protocol depending on the results of the first 11 patients and the projected recruitment
      rate.

      Safety monitoring Adverse events as recorded in the aortic database of historical controls
      will form the basis of the clinical research form (CRF) and are specifically outlined and
      defined below.

      The conduct of anesthesia and surgery will be at the discretion of the attending surgeon and
      anesthesiologist. Following heparin reversal with protamine sulphate and administration of
      30mcg/kg DDAVP and 5g aminocaproic acid as per standard practice for these cases, surgical
      hemorrhage will be excluded by the attending surgeon. The dose of fibrinogen concentrate will
      be administered as described in the Figure. RiaSTAP will only be administered if
      coagulopathic bleeding is observed by the surgeon such that it will be used for the
      treatment, not the prevention of bleeding.

      It is standard practice for the surgeon to report coagulopathic bleeding (as defined by lack
      of visible clot in the wound, soaking of swabs with blood and/or continued aspiration of
      blood into the cell-saver device) before we administer blood products and/or rFVIIa after
      separation from bypass and following administration of protamine to reverse heparin,
      aminocaproic acid to inhibit fibrinolysis and DDAVP to augment platelet function.

      The Food and Drug (FDA) approved dose of 70mg/kg will be used. Following the dosage of
      fibrinogen concentrate subsequent care of the patient will not be governed by the study
      protocol. Specifically, transfusion of blood products are suggested in the flow diagram above
      and transfusion guidelines have been developed by Dr Ian Welsby and Dr Chad Hughes in August
      2009 in response to difficulties managing such cases and both of these will be available for
      use, BUT will only be applied at the discretion of the attending anesthesiologist and
      surgeon.

      Proposed laboratory tests in addition to standard of care Time points

        1. Baseline Anesthesia induction

        2. Pre RiaSTAP After separation from cardio pulmonary bypass (CPB), after desired protamine
           given

        3. Post RiaSTAP Ten minutes after RiaSTAP administered

        4. Post op On admission to intensive care unit (ICU)

        5. Post op 24 hours after surgery Plasma Heparin level (to avoid misinterpretation of clot
           based factor assays) Thrombin clot time (as above) Fibrinogen (Clauss method) Clotting
           Factor Levels Endogenous thrombin potential Whole blood Rotational Thromboelastometry
           (ROTEM) including Fibrinogen Test (FIBTEM) but not Lysis Test (APTEM) MEA platelet
           aggregometry (to be provided by CSL Behring)

      20ml of blood will be drawn at each timepoint, total 100ml.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2010</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Fibrinogen Level Change</measure>
    <time_frame>Anesthesia Induction (Baseline), Pre RiaSTAP (est. 4 hr after baseline), Post RiaSTAP (est: 10 minutes after RiaSTAP administered), ICU Admission (est. 6 hours after baseline), 24 Hour post op (est: 24-30 hr after baseline)</time_frame>
    <description>Fibrinogen levels will be assessed only at the timepoints listed in the timeframe and for a maximum of 24 hours.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Packed Red Blood Cell Transfusion</measure>
    <time_frame>Anesthesia Induction (Baseline), after CPB, ICU Admission (est. 6 hours after baseline) to post op day 2 (est: 30- 54 hr after baseline)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fresh Frozen Plasma Transfusion</measure>
    <time_frame>Anesthesia Induction (Baseline), after CPB, ICU Admission (est. 6 hours after baseline) to post op day 2 (est: 30- 54 hr after baseline)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Platelet Transfusion</measure>
    <time_frame>Anesthesia Induction (Baseline), after CPB, ICU Admission (est. 6 hours after baseline) to post op day 2 (est: 30- 54 hr after baseline)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cryoprecipitate Transfusion</measure>
    <time_frame>Anesthesia Induction (Baseline), after CPB, ICU Admission (est. 6 hours after baseline) to post op day 2 (est: 30- 54 hr after baseline)</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">23</enrollment>
  <condition>Coagulopathic Bleeding</condition>
  <arm_group>
    <arm_group_label>RiaSTAP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One time dose of 70 mg/kg will be administered intravenously.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RiaSTAP</intervention_name>
    <description>One time dose of 70 mg/kg will be administered intravenously.</description>
    <arm_group_label>RiaSTAP</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Elective, adult aortic reconstruction involving a hemi-arch replacement at DUMC.

        Exclusion Criteria:

          -  Concomitant procedures such as CABG , stents (within the last 3 years), refusal of
             blood transfusion, recent MI (within the last 3 months), pregnancy, INR &gt; 1.1,
             platelet inhibitor drugs within 5 days of surgery (aspirin 325 mg within 48 hours of
             surgery), platelet count &lt; 150,000, age &lt;18 years, inability to obtain written
             informed consent, known coagulopathy including a history of recent coumadin therapy.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ian Welsby, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Rahe-Meyer N, Pichlmaier M, Haverich A, Solomon C, Winterhalter M, Piepenbrock S, Tanaka KA. Bleeding management with fibrinogen concentrate targeting a high-normal plasma fibrinogen level: a pilot study. Br J Anaesth. 2009 Jun;102(6):785-92. doi: 10.1093/bja/aep089. Epub 2009 May 2.</citation>
    <PMID>19411671</PMID>
  </reference>
  <reference>
    <citation>Peyvandi F, Haertel S, Knaub S, Mannucci PM. Incidence of bleeding symptoms in 100 patients with inherited afibrinogenemia or hypofibrinogenemia. J Thromb Haemost. 2006 Jul;4(7):1634-7.</citation>
    <PMID>16839371</PMID>
  </reference>
  <reference>
    <citation>Rahe-Meyer N, Solomon C, Winterhalter M, Piepenbrock S, Tanaka K, Haverich A, Pichlmaier M. Thromboelastometry-guided administration of fibrinogen concentrate for the treatment of excessive intraoperative bleeding in thoracoabdominal aortic aneurysm surgery. J Thorac Cardiovasc Surg. 2009 Sep;138(3):694-702. doi: 10.1016/j.jtcvs.2008.11.065. Epub 2009 May 17.</citation>
    <PMID>19698858</PMID>
  </reference>
  <reference>
    <citation>Kreuz W, Meili E, Peter-Salonen K, Dobrkovská A, Devay J, Haertel S, Krzensk U, Egbring R. Pharmacokinetic properties of a pasteurised fibrinogen concentrate. Transfus Apher Sci. 2005 Jun;32(3):239-46.</citation>
    <PMID>15919241</PMID>
  </reference>
  <reference>
    <citation>Lind P, Hedblad B, Stavenow L, Janzon L, Eriksson KF, Lindgärde F. Influence of plasma fibrinogen levels on the incidence of myocardial infarction and death is modified by other inflammation-sensitive proteins: a long-term cohort study. Arterioscler Thromb Vasc Biol. 2001 Mar;21(3):452-8.</citation>
    <PMID>11231928</PMID>
  </reference>
  <verification_date>January 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 9, 2011</study_first_submitted>
  <study_first_submitted_qc>February 17, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 21, 2011</study_first_posted>
  <results_first_submitted>January 16, 2014</results_first_submitted>
  <results_first_submitted_qc>May 15, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 16, 2014</results_first_posted>
  <last_update_submitted>December 5, 2014</last_update_submitted>
  <last_update_submitted_qc>December 5, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 25, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>RiaSTAP</title>
          <description>RiaSTAP: One time dose of 70 mg/kg will be administered intravenously.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>did not get dosed</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>RiaSTAP</title>
          <description>RiaSTAP: One time dose of 70 mg/kg will be administered intravenously</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="23"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52" spread="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Fibrinogen Level Change</title>
        <description>Fibrinogen levels will be assessed only at the timepoints listed in the timeframe and for a maximum of 24 hours.</description>
        <time_frame>Anesthesia Induction (Baseline), Pre RiaSTAP (est. 4 hr after baseline), Post RiaSTAP (est: 10 minutes after RiaSTAP administered), ICU Admission (est. 6 hours after baseline), 24 Hour post op (est: 24-30 hr after baseline)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>RiaSTAP</title>
            <description>One time dose of 70 mg/kg will be administered intravenously.</description>
          </group>
        </group_list>
        <measure>
          <title>Fibrinogen Level Change</title>
          <description>Fibrinogen levels will be assessed only at the timepoints listed in the timeframe and for a maximum of 24 hours.</description>
          <units>mg/dl</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anesthesia Induction,I</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="317" spread="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pre RiaSTAP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="235" spread="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post RiaSTAP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="331" spread="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ICU admission</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="312" spread="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 hours post op</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="372" spread="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Packed Red Blood Cell Transfusion</title>
        <time_frame>Anesthesia Induction (Baseline), after CPB, ICU Admission (est. 6 hours after baseline) to post op day 2 (est: 30- 54 hr after baseline)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>RiaSTAP</title>
            <description>One time dose of 70 mg/kg will be administered intravenously.</description>
          </group>
        </group_list>
        <measure>
          <title>Packed Red Blood Cell Transfusion</title>
          <units>units</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" lower_limit="0" upper_limit="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Fresh Frozen Plasma Transfusion</title>
        <time_frame>Anesthesia Induction (Baseline), after CPB, ICU Admission (est. 6 hours after baseline) to post op day 2 (est: 30- 54 hr after baseline)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>RiaSTAP</title>
            <description>One time dose of 70 mg/kg will be administered intravenously.
RiaSTAP: One time dose of 70 mg/kg will be administered intravenously.</description>
          </group>
        </group_list>
        <measure>
          <title>Fresh Frozen Plasma Transfusion</title>
          <units>mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1000" lower_limit="1000" upper_limit="1500"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Platelet Transfusion</title>
        <time_frame>Anesthesia Induction (Baseline), after CPB, ICU Admission (est. 6 hours after baseline) to post op day 2 (est: 30- 54 hr after baseline)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>RiaSTAP</title>
            <description>One time dose of 70 mg/kg will be administered intravenously.
RiaSTAP: One time dose of 70 mg/kg will be administered intravenously.</description>
          </group>
        </group_list>
        <measure>
          <title>Platelet Transfusion</title>
          <units>mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="400" lower_limit="274" upper_limit="592"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cryoprecipitate Transfusion</title>
        <time_frame>Anesthesia Induction (Baseline), after CPB, ICU Admission (est. 6 hours after baseline) to post op day 2 (est: 30- 54 hr after baseline)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>RiaSTAP</title>
            <description>One time dose of 70 mg/kg will be administered intravenously.
RiaSTAP: One time dose of 70 mg/kg will be administered intravenously.</description>
          </group>
        </group_list>
        <measure>
          <title>Cryoprecipitate Transfusion</title>
          <units>mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20" spread="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>RiaSTAP</title>
          <description>RiaSTAP: One time dose of 70 mg/kg will be administered intravenously.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Postoperative atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Ian Welsby</name_or_title>
      <organization>Duke University Medical Center</organization>
      <phone>919-668-2699</phone>
      <email>ian.welsby@duke.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

